Piramal Pharma Ltd Analyst Rating
based on 7 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 7 analysts offering long term price targets for Piramal Pharma Ltd. An average target of ₹292
Source: S&P Global Market Intelligence
Piramal Pharma Ltd Share analysis
Piramal Pharma Ltd price forecast by 7 analysts
Upside of14.51%
High
₹340
Target
₹292.00
Low
₹260
Piramal Pharma Ltd target price ₹292, a slight upside of 14.51% compared to current price of ₹255. According to 7 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Piramal Pharma Ltd revenue growth forecast
Expected growth rate Q1, FY2026:29.93%
Forecast
Actual
Including amortisation and stock based compensations
Piramal Pharma Ltd EPS growth forecast
EPS estimate Q1, FY2026:3315.38%
Forecast
Actual
Source: S&P Global Market Intelligence
Piramal Pharma Ltd Performance
Day's Low
Day's High
₹250.65Day's Price Range₹257.452 Week's Low
52 Week's High
₹114.3552-Week Price Range₹307.9
| Returns % | |
| 1 Month Return | + 1.88 % |
| 3 Month Return | + 12.68 % |
| 1 Year Return | + 83.98 % |
| Market Stats | |
| Previous Close | ₹255.40 |
| Open | ₹256.15 |
| Volume | 19.98L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹33,806.58Cr |
Piramal Pharma Ltd Key Statistics
| P/E Ratio | 728.57 |
| PEG Ratio | 501.55 |
| Market Cap | ₹33,806.58 Cr |
| P/B Ratio | 2.54 |
| EPS | 0.13 |
| Dividend Yield | 0.09 |
| Sector | Pharmaceuticals |
| ROE | 6.53 |
Piramal Pharma Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹33,806.58 Cr | 6.84% | 0.58 | ₹17 Cr | ₹8,171 Cr | |
| BUY | ₹28,426.00 Cr | 112.52% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| BUY | ₹17,481.58 Cr | 28.58% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| NA | ₹6,532.30 Cr | 5.83% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹15,623.72 Cr | 48.35% | 0.68 | ₹218 Cr | ₹1,296 Cr |
Piramal Pharma Ltd Mutual Fund Holdings
About Piramal Pharma Ltd
Share Price: ₹255.00 per share as on 24 Dec, 2024 04:01 PM
Market Capitalisation: ₹33,806.58Cr as of today
Revenue: ₹2,241.75Cr as on September 2024 (Q3 24)
Net Profit: ₹22.59Cr as on September 2024 (Q3 24)
Listing date: 19 Oct, 2022
Chairperson Name: Nandini Piramal
| Organisation | Piramal Pharma Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Piramal Pharma Ltd
Piramal Pharma Set for Growth in CDMO Sector - 24 Dec, 2024
Motilal Oswal highlights Piramal Pharma's potential growth due to increased CDMO inquiries and expansion in complex hospital generics. The firm projects net profit to rise to Rs 700 crore by FY26 from Rs 56 crore in FY24.Piramal Pharma Receives Buy Rating from JM Financial - 20 Dec, 2024
Piramal Pharma is highlighted by JM Financial with a buy rating and a target price of ₹340, suggesting significant upside potential. The company is expected to grow 15% over FY24-27, driven by its CDMO business and consumer health segment.Piramal Pharma Gains as JM Financial Initiates Buy - 17 Dec, 2024
Piramal Pharma shares surged after JM Financial initiated coverage with a Buy rating and a target price of Rs 340, highlighting strong growth potential and attractive valuation compared to peers.Piramal Pharma Reports Revenue Growth and Stock Increase - 10 Dec, 2024
Piramal Pharma's shares rose by 1.08% to Rs. 258.50. The company reported a 17.45% revenue increase from Rs. 1,960.57 Crores to Rs. 2,302.86 Crores in Q2FY25, with profits rising from Rs. 5.02 Crores to Rs. 22.59 Crores.Piramal Pharma Faces Pressure Amid Biosecure Act Exclusion - 09 Dec, 2024
Piramal Pharma announced a $407,400 settlement with VetDC, Inc for rejected product batches. Subsequently, shares fell over 2% due to the exclusion of the US Biosecure Act from a defense bill, impacting investor sentiment.Piramal Pharma Settles Dispute with VetDC - 06 Dec, 2024
Piramal Pharma has settled a dispute with VetDC, Inc for USD 407,400 regarding rejected product batches. The company asserts this settlement will not significantly impact its financial position.Piramal Pharma Shares Surge Over 5% - 02 Dec, 2024
Piramal Pharma shares rose 5.25% to ₹282.85, with a market cap of ₹37,498.79 crore. The stock's strong performance reflects renewed investor confidence and aligns with positive market sentiment in the pharmaceutical sector.Piramal Pharma Shares Surge Amid Positive Market Sentiment - 29 Nov, 2024
Piramal Pharma's shares surged 8%, opening at ₹249.65 and reaching a high of ₹266.90. The stock remains below its 52-week high of ₹307.85, indicating growth potential. Strong market outlook and investor confidence contribute to its positive performance.Piramal Pharma Reports Growth Amid Financial Challenges - 28 Nov, 2024
Piramal Pharma Limited reported a 15% revenue growth for FY24, driven by CDMO and ICH segments. Despite narrowing losses, high valuations and weak profitability metrics raise concerns, leading to a recommendation to avoid the stock.
Insights on Piramal Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 10.12% to 11.21% in Sep 2024 quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, PPLPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -88.64 Cr → 22.59 Cr (in ₹), with an average increase of 492.4% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 13.42% to 13.73% in Sep 2024 quarter
- POSITIVE IMPACT
Price Rise
In the last 6 months, PPLPHARMA stock has moved up by 59.6%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 1.99K Cr → 2.32K Cr (in ₹), with an average increase of 14.1% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 34.95% of holdings in Sep 2024 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 20.21% to 19.07% in Sep 2024 quarter
Piramal Pharma Ltd Financials
Index Inclusions
Piramal Pharma Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 34.95% | 0.00 | |
| Foreign Institutions | 13.73% | 2.34 | |
| Mutual Funds | 11.21% | 10.87 | |
| Retail Investors | 19.07% | ||
| Others | 21.04% |
Piramal Pharma Ltd Key Indicators
Piramal Pharma Ltd Valuation
Piramal Pharma Ltd in the last 5 years
Lowest (-516.41x)
January 5, 2024
Industry (56.56x)
December 24, 2024
Today (728.57x)
December 24, 2024
Highest (2011.42x)
June 25, 2024
Piramal Pharma Ltd Earnings and Dividends
Piramal Pharma Ltd Earnings Results
Piramal Pharma Ltd’s net profit jumped 350% since last year same period to ₹22.59Cr in the Q2 2024-2025. On a quarterly growth basis, Piramal Pharma Ltd has generated 125.49% jump in its net profits since last 3-months.
Read More about Earnings ResultsPiramal Pharma Ltd Dividends May,2024
In the quarter ending March 2024, Piramal Pharma Ltd has declared dividend of ₹0.11 - translating a dividend yield of 0.04%.
Read More about Dividends
Piramal Pharma Ltd Technicals Summary
Bearish
Neutral
Bullish
Piramal Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Piramal Pharma Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Piramal Pharma Ltd shares.
Piramal Pharma Ltd (PPLPHARMA) share price today is ₹255
Piramal Pharma Ltd is listed on NSE
Piramal Pharma Ltd is listed on BSE
- Today’s highest price of Piramal Pharma Ltd is ₹257.4.
- Today’s lowest price of Piramal Pharma Ltd is ₹250.65.
PE Ratio of Piramal Pharma Ltd is 728.57
PE ratio = Piramal Pharma Ltd Market price per share / Piramal Pharma Ltd Earnings per share
Today’s traded volume of Piramal Pharma Ltd(PPLPHARMA) is 19.98L.
Today’s market capitalisation of Piramal Pharma Ltd(PPLPHARMA) is ₹33806.58Cr.
| Piramal Pharma Ltd(PPLPHARMA | Price |
|---|---|
52 Week High | ₹307.9 |
52 Week Low | ₹114.35 |
Piramal Pharma Ltd(PPLPHARMA) share price is ₹255. It is down -17.18% from its 52 Week High price of ₹307.9
Piramal Pharma Ltd(PPLPHARMA) share price is ₹255. It is up 123.00% from its 52 Week Low price of ₹114.35
| Piramal Pharma Ltd(PPLPHARMA | Returns |
|---|---|
1 Day Returns | -0.4% |
1 Month Returns | 1.88% |
3 Month Returns | 12.68% |
1 Year Returns | 83.98% |